Ceftolozane/Tazobactam
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Cystic Fibrosis
Conditions
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation, Pseudomonas Aeruginosa Infection
Trial Timeline
Sep 1, 2015 → Oct 1, 2016
NCT ID
NCT02421120About Ceftolozane/Tazobactam
Ceftolozane/Tazobactam is a approved stage product being developed by Merck for Cystic Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT02421120. Target conditions include Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation, Pseudomonas Aeruginosa Infection.
What happened to similar drugs?
20 of 20 similar drugs in Cystic Fibrosis were approved
Approved (20) Terminated (7) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04223752 | Phase 1 | Completed |
| NCT03002506 | Approved | Terminated |
| NCT02620774 | Phase 1 | Completed |
| NCT02421120 | Approved | Completed |
Competing Products
20 competing products in Cystic Fibrosis